McAndrews Secures Another Victory for Client Accord Healthcare, Inc.
01.02.25
On Dec. 30, 2024, the United States Court of Appeals for the Federal Circuit affirmed the April 2023 District Court opinion in favor of McAndrews client Accord Healthcare, Inc.
Accord filed an abbreviated new drug application (ANDA) for approval to market a generic version of Purdue Pharma’s OxyContin® branded extended release oxycodone hydrochloride tablets. Purdue Pharma alleged that Accord’s proposed ANDA product would infringe five Purdue patents if marketed. Accord asserted that each of the five patents was invalid.
The Federal Circuit issued a decision siding with Accord, invalidating all of the asserted claims of the five Purdue patents.
Accord is represented by Alex Menchaca, Ben Mahon, and Brad Loren.